How can we improve the acceptability of vaccination against Human Papillomavirus (HPV) in France? An original qualitative study with focus groups comprising parents and school staff, interviewed separately.

Fiche publication

Date publication

juin 2023

Journal

Vaccine

Auteurs

Membres identifiés du Cancéropôle Est :
Pr THILLY Nathalie

Tous les auteurs :
Ailloud J, Branchereau M, Fall E, Juneau C, Partouche H, Bonnay S, Oudin-Doglioni D, Michel M, Gagneux-Brunon A, Bruel S, Thilly N, Gauchet A,

Lien Pubmed

https://www.ncbi.nlm.nih.gov/pubmed/37344259

Résumé

It has been proven that vaccination is effective against Human Papillomavirus (HPV) infections, genital warts, and pre-cancerous and cancerous cervical lesions. Nevertheless, the HPV vaccine coverage of 37.4 % in 2021 in France is one of the lowest in Europe. To explore and understand the reason why French population is so late compared to its neighbours, we carried out focus groups with mothers and with National Education school staff. We aimed to identify knowledge and perceptions of HPV in both study populations, as well as factors influencing HPV vaccination.